The Latest Breaking News from Indivior

Indivior (INDV) is up 90% since April and has consistently hit new highs, driven by optimism for Sublocade. INDV stock set its latest 52-week high in morning trading on Aug. 8. Technical indicators are overwhelmingly bullish. Indivior has a 100% “Buy” rating from Barchart. Despite the current momentum, INDV is...

Firm behind opioid addiction treatment drugs quits London Stock Exchange after moving primary to US last year

Rolling, live coverage of business, economics and financial markets as British bond yields rise amid expectations of stubbornly high interest rates

The company that makes the opioid addiction treatment drug Suboxone has reached a $102.5 million settlement of antitrust claims with 41 states and the District of Columbia

Opvee is similar to naloxone, the life-saving drug that has been used for decades to quickly counter overdoses of heroin, fentanyl and prescription painkillers.

U.S. health regulators have approved a new nasal spray to reverse overdoses due to fentanyl and other powerful opioids

Last week, Addex Therapeutics Ltd (NASDAQ:ADXN) terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow rate of patient recruitment.  Addex is suspending its financial guidance. Hence HC Wainwright downgraded its rating to Neutral from Buy without a price target, as dipraglurant…

Addex Therapeutics Ltd (NASDAQ:ADXN) has terminated the Phase 2b/3 study of dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients.  Data readout from the trial was expected in 1H of 2023. The company attributes this to the consequences of COVID-19-related patient concerns about participation in studies, staffing…

Indivior PLC (OTCPK:INVVY) (LON:INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD).